DexCom, Inc. (DXCM) Raised to Sell at BidaskClub

BidaskClub upgraded shares of DexCom, Inc. (NASDAQ:DXCM) from a strong sell rating to a sell rating in a report published on Wednesday, August 9th.

A number of other equities research analysts have also recently issued reports on DXCM. B. Riley restated a buy rating and issued a $95.00 price objective on shares of DexCom in a research note on Sunday, May 7th. BMO Capital Markets restated an outperform rating and issued a $90.00 price objective (down from $105.00) on shares of DexCom in a research note on Wednesday, August 2nd. Stephens restated an overweight rating and issued a $83.00 price objective (down from $95.00) on shares of DexCom in a research note on Wednesday, August 2nd. Oppenheimer Holdings, Inc. set a $92.00 price objective on DexCom and gave the company a buy rating in a research note on Wednesday, August 2nd. Finally, Zacks Investment Research cut DexCom from a hold rating to a sell rating in a research note on Friday, August 4th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have given a buy rating to the stock. The company presently has an average rating of Buy and an average price target of $87.00.

DexCom (NASDAQ DXCM) traded up 0.58% during trading on Wednesday, hitting $73.20. 1,234,880 shares of the company traded hands. The company’s market capitalization is $6.34 billion. The stock has a 50 day moving average price of $70.65 and a 200 day moving average price of $74.91. DexCom has a 12-month low of $57.68 and a 12-month high of $96.38.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.07. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The business had revenue of $170.60 million for the quarter, compared to analysts’ expectations of $166.54 million. During the same period in the previous year, the business posted ($0.24) EPS. The firm’s quarterly revenue was up 24.3% compared to the same quarter last year. On average, equities analysts anticipate that DexCom will post ($0.77) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.com-unik.info/2017/08/19/dexcom-inc-dxcm-upgraded-to-sell-at-bidaskclub-updated.html.

In other news, EVP Richard Doubleday sold 3,182 shares of the business’s stock in a transaction dated Tuesday, May 23rd. The stock was sold at an average price of $68.29, for a total transaction of $217,298.78. Following the completion of the transaction, the executive vice president now owns 72,395 shares of the company’s stock, valued at $4,943,854.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kevin R. Sayer sold 6,000 shares of the company’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $69.07, for a total value of $414,420.00. The disclosure for this sale can be found here. Insiders have sold 33,726 shares of company stock valued at $2,376,466 in the last three months. 1.70% of the stock is owned by insiders.

A number of hedge funds have recently modified their holdings of DXCM. Independent Portfolio Consultants Inc. raised its stake in shares of DexCom by 0.4% in the second quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock valued at $183,000 after buying an additional 9 shares in the last quarter. Bbva Compass Bancshares Inc. raised its stake in shares of DexCom by 1.9% in the second quarter. Bbva Compass Bancshares Inc. now owns 3,670 shares of the medical device company’s stock valued at $268,000 after buying an additional 69 shares in the last quarter. Mn Services Vermogensbeheer B.V. raised its stake in shares of DexCom by 3.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,254 shares of the medical device company’s stock valued at $179,000 after buying an additional 83 shares in the last quarter. Public Employees Retirement Association of Colorado raised its stake in shares of DexCom by 0.4% in the second quarter. Public Employees Retirement Association of Colorado now owns 18,613 shares of the medical device company’s stock valued at $1,362,000 after buying an additional 83 shares in the last quarter. Finally, King Luther Capital Management Corp raised its stake in shares of DexCom by 0.7% in the first quarter. King Luther Capital Management Corp now owns 12,105 shares of the medical device company’s stock valued at $1,026,000 after buying an additional 90 shares in the last quarter.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

What are top analysts saying about DexCom Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DexCom Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit